TSC2 and bladder transitional cell carcinoma: We evaluated further the in vivo antitumor activity of bi-steric mTORC1-selective inhibitors by testing RMC-5552 in 3 human BLCA PDX models with TSC1/TSC2 deficiency, including the same model in which RMC-6272 was assessed.